M. Nechaeva

Atezolizumab and <i>nab</i>-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

Leisha A. Emens, Luciana Molinero, Sherene Loi et al. · JNCI Journal of the National Cancer Institute · 2021 · 306 citations · Full text

Medicine, Oncology, Pharmacology +17

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 284 citations · Full text

Medicine, Oncology, Pharmacology +13

Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + <i>nab</i>-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer

LA Emens, Sherene Loi, HS Rugo et al. · Cancer Research · 2019 · 82 citations

Medicine, Oncology, Pharmacology +17

FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Salah‐Eddin Al‐Batran, Martin Schüler, Zanete Zvirbule et al. · Journal of Clinical Oncology · 2016 · 46 citations

Medicine, Oncology, Pharmacology +17

296P Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial

Leisha A. Emens, Luciana Molinero, Sylvia Adams et al. · Annals of Oncology · 2020 · 30 citations · Full text

Medicine, Oncology, Pharmacology +17